Work

Acute Effects of Aromatase Inhibitor Therapy for Breast Cancer on Glycemic Control

Year: 2026
Type: dissertation
Abstract: Aromatase inhibitor (AI) therapy is a key component of adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer; however, the profound estrogen suppression induced by AI therapy has raised concern regarding potential cardiometabolic consequences, including impaired glycemic regulation. Despite these concerns, little is known about the timing with which metabolic alterations emerge following initiation of endocrine therapy. As AI therapy rapidly supresses circulating estrogen within days of initiation, the early treatment period represents a biologically relevant window to examine potential acute metabolic effects. Continuous glucose monitoring (CGM) offers a novel opportunity to characterize short-term changes in free-living glycemic regulation with high temporal resolution. The purpose of this exploratory study was to examine acute changes in glycemic regulation during the three days before and after AI initiation. Seven postmenopausal breast cancer survivors initiating AI therapy and seven age- and body mass index-matched non-cancer control participants completed six days of CGM monitoring using the Dexcom G7 system. The control participants completed an identical monitoring period without treatment exposure. Outcomes included mean 24-hour glucose, peak 24-hour glucose, and 24-hour glucose area under the curve. Initiation of AI therapy was not associated with detectable short-term changes in glycemic regulation, and the magnitude of change did not differ between BC survivors and non-cancer controls. These preliminary findings suggest that AI initiation does not produce immediate alterations in free-living glycemic regulation during the first week of treatment. Further research with larger samples and longer follow-up is required to determine whether metabolic alterations emerge with prolonged estrogen suppression and to better characterize the trajectory of cardiometabolic risk among breast cancer survivors receiving AI therapy.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7204021441
Cites: 131
Cited by:
Related to: 10